MarketCap
Facebook
X
TelegramGeschäftsbericht 2023
hinzugefügt 08.03.2024
Emergent BioSolutions Langfristige Verbindlichkeiten 2011-2026 | EBS
Langfristige Verbindlichkeiten Jährlich Emergent BioSolutions
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 1.02 B | 1.02 B | 57.8 M | 268 M | 284 M | 299 M | 80.8 M | 60.2 M | 59.1 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.02 B | 57.8 M | 350 M |
Langfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Zynerba Pharmaceuticals
ZYNE
|
110 K | - | - | $ 55.5 M |  USA |
 |
Alimera Sciences
ALIM
|
46.5 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
7.44 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
274 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
104 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
10.7 M | $ 2.69 | -0.56 % | $ 1.42 B |  Canada |
 |
Agile Therapeutics
AGRX
|
16.4 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
3.83 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
26.4 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
36.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
8.8 B | - | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
316 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
6.61 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
38.2 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Athenex
ATNX
|
157 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
134 M | $ 21.5 | -0.12 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
102 M | $ 6.03 | -10.27 % | $ 374 M | USA |
 |
Harrow Health
HROW
|
19.8 M | $ 54.06 | 8.3 % | $ 1.76 B | USA |
 |
Jupiter Wellness
JUPW
|
6.38 K | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
1.71 M | $ 1.23 | 1.65 % | $ 21.5 M |  China |
 |
OrganiGram Holdings
OGI
|
107 M | $ 1.7 | -1.74 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
26.5 B | $ 7.51 | 4.16 % | $ 2.74 B | Canada |
 |
Lannett Company
LCI
|
677 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
11.4 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
23.9 M | $ 3.95 | -0.77 % | $ 55.5 M | USA |
 |
Organogenesis Holdings
ORGO
|
105 M | $ 4.36 | -5.93 % | $ 574 M | USA |
 |
Sundial Growers
SNDL
|
1.03 M | $ 1.72 | -1.41 % | $ 3.37 M | Canada |
 |
Pacira BioSciences
PCRX
|
368 M | $ 25.21 | 3.07 % | $ 1.17 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
991 K | $ 3.73 | 2.46 % | $ 4.63 M | USA |
 |
Aurora Cannabis
ACB
|
681 M | $ 4.28 | -1.41 % | $ 86.3 M | Canada |
 |
Rockwell Medical
RMTI
|
11.6 M | $ 0.98 | 13.92 % | $ 22.9 M | USA |
 |
PetIQ
PETQ
|
456 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
4.28 B | $ 14.36 | 3.42 % | $ 1.97 B | USA |
 |
ProPhase Labs
PRPH
|
7.94 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
6.71 M | $ 2.28 | 0.58 % | $ 308 M | USA |
 |
Radius Health
RDUS
|
200 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
111 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
2.49 M | $ 1.11 | -4.31 % | $ 4.79 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 4.11 | -6.06 % | $ 124 M | USA |
 |
OptiNose
OPTN
|
130 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
115 M | $ 9.62 | 5.25 % | $ 683 M | USA |
 |
PLx Pharma
PLXP
|
34 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
21.2 M | $ 5.33 | -2.14 % | $ 218 M | USA |
 |
SCYNEXIS
SCYX
|
53.4 M | $ 0.64 | -0.03 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
13.2 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
570 M | $ 9.43 | -3.03 % | $ 5.83 B | Canada |
 |
TherapeuticsMD
TXMD
|
246 M | $ 1.79 | 8.78 % | $ 18.7 M | USA |
 |
Zomedica Corp.
ZOM
|
275 | - | -0.21 % | $ 98 M | USA |